203 related articles for article (PubMed ID: 37989747)
21. SETD2 loss perturbs the kidney cancer epigenetic landscape to promote metastasis and engenders actionable dependencies on histone chaperone complexes.
Xie Y; Sahin M; Sinha S; Wang Y; Nargund AM; Lyu Y; Han S; Dong Y; Hsieh JJ; Leslie CS; Cheng EH
Nat Cancer; 2022 Feb; 3(2):188-202. PubMed ID: 35115713
[TBL] [Abstract][Full Text] [Related]
22. SETD2 Deficiency Confers Sensitivity to Dual Inhibition of DNA Methylation and PARP in Kidney Cancer.
Zhou X; Sekino Y; Li HT; Fu G; Yang Z; Zhao S; Gujar H; Zu X; Weisenberger DJ; Gill IS; Tulpule V; D'souza A; Quinn DI; Han B; Liang G
Cancer Res; 2023 Nov; 83(22):3813-3826. PubMed ID: 37695044
[TBL] [Abstract][Full Text] [Related]
23.
Su X; Zhang J; Mouawad R; Compérat E; Rouprêt M; Allanic F; Parra J; Bitker MO; Thompson EJ; Gowrishankar B; Houldsworth J; Weinstein JN; Tost J; Broom BM; Khayat D; Spano JP; Tannir NM; Malouf GG
Cancer Res; 2017 Sep; 77(18):4835-4845. PubMed ID: 28754676
[TBL] [Abstract][Full Text] [Related]
24. Integrative radiogenomics analysis for predicting molecular features and survival in clear cell renal cell carcinoma.
Zeng H; Chen L; Wang M; Luo Y; Huang Y; Ma X
Aging (Albany NY); 2021 Mar; 13(7):9960-9975. PubMed ID: 33795526
[TBL] [Abstract][Full Text] [Related]
25. An actin-WHAMM interaction linking SETD2 and autophagy.
Seervai RNH; Grimm SL; Jangid RK; Tripathi DN; Coarfa C; Walker CL
Biochem Biophys Res Commun; 2021 Jun; 558():202-208. PubMed ID: 33036756
[TBL] [Abstract][Full Text] [Related]
26. BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies.
Piva F; Santoni M; Matrana MR; Satti S; Giulietti M; Occhipinti G; Massari F; Cheng L; Lopez-Beltran A; Scarpelli M; Principato G; Cascinu S; Montironi R
Expert Rev Mol Diagn; 2015; 15(9):1201-10. PubMed ID: 26166446
[TBL] [Abstract][Full Text] [Related]
27. SETD2 is required for DNA double-strand break repair and activation of the p53-mediated checkpoint.
Carvalho S; Vítor AC; Sridhara SC; Martins FB; Raposo AC; Desterro JM; Ferreira J; de Almeida SF
Elife; 2014 May; 3():e02482. PubMed ID: 24843002
[TBL] [Abstract][Full Text] [Related]
28. Setd2 deficiency impairs hematopoietic stem cell self-renewal and causes malignant transformation.
Zhang YL; Sun JW; Xie YY; Zhou Y; Liu P; Song JC; Xu CH; Wang L; Liu D; Xu AN; Chen Z; Chen SJ; Sun XJ; Huang QH
Cell Res; 2018 Apr; 28(4):476-490. PubMed ID: 29531312
[TBL] [Abstract][Full Text] [Related]
29. Deficiency of Histone Methyltransferase SET Domain-Containing 2 in Liver Leads to Abnormal Lipid Metabolism and HCC.
Li XJ; Li QL; Ju LG; Zhao C; Zhao LS; Du JW; Wang Y; Zheng L; Song BL; Li LY; Li L; Wu M
Hepatology; 2021 May; 73(5):1797-1815. PubMed ID: 33058300
[TBL] [Abstract][Full Text] [Related]
30. Extensive intratumor regional epigenetic heterogeneity in clear cell renal cell carcinoma targets kidney enhancers and is associated with poor outcome.
El Khoury LY; Pan X; Hlady RA; Wagner RT; Shaikh S; Wang L; Humphreys MR; Castle EP; Stanton ML; Ho TH; Robertson KD
Clin Epigenetics; 2023 Apr; 15(1):71. PubMed ID: 37120552
[TBL] [Abstract][Full Text] [Related]
31. Prognostic Impact of Loss of SETD2 in Clear Cell Renal Cell Carcinoma.
Santos VE; da Costa WH; Bezerra SM; da Cunha IW; Nobre JQC; Brazão ES; Meduna RR; Rocha MM; Fornazieri L; Zequi SC
Clin Genitourin Cancer; 2021 Aug; 19(4):339-345. PubMed ID: 33839039
[TBL] [Abstract][Full Text] [Related]
32. Expression and Mutation Patterns of PBRM1, BAP1 and SETD2 Mirror Specific Evolutionary Subtypes in Clear Cell Renal Cell Carcinoma.
Bihr S; Ohashi R; Moore AL; Rüschoff JH; Beisel C; Hermanns T; Mischo A; Corrò C; Beyer J; Beerenwinkel N; Moch H; Schraml P
Neoplasia; 2019 Feb; 21(2):247-256. PubMed ID: 30660076
[TBL] [Abstract][Full Text] [Related]
33. SETD2 loss-of-function promotes renal cancer branched evolution through replication stress and impaired DNA repair.
Kanu N; Grönroos E; Martinez P; Burrell RA; Yi Goh X; Bartkova J; Maya-Mendoza A; Mistrík M; Rowan AJ; Patel H; Rabinowitz A; East P; Wilson G; Santos CR; McGranahan N; Gulati S; Gerlinger M; Birkbak NJ; Joshi T; Alexandrov LB; Stratton MR; Powles T; Matthews N; Bates PA; Stewart A; Szallasi Z; Larkin J; Bartek J; Swanton C
Oncogene; 2015 Nov; 34(46):5699-708. PubMed ID: 25728682
[TBL] [Abstract][Full Text] [Related]
34. Dynamic reprogramming of DNA methylation in SETD2-deregulated renal cell carcinoma.
Tiedemann RL; Hlady RA; Hanavan PD; Lake DF; Tibes R; Lee JH; Choi JH; Ho TH; Robertson KD
Oncotarget; 2016 Jan; 7(2):1927-46. PubMed ID: 26646321
[TBL] [Abstract][Full Text] [Related]
35. SETD2: an epigenetic modifier with tumor suppressor functionality.
Li J; Duns G; Westers H; Sijmons R; van den Berg A; Kok K
Oncotarget; 2016 Aug; 7(31):50719-50734. PubMed ID: 27191891
[TBL] [Abstract][Full Text] [Related]
36. Metabolic and Lipidomic Reprogramming in Renal Cell Carcinoma Subtypes Reflects Regions of Tumor Origin.
Schaeffeler E; Büttner F; Reustle A; Klumpp V; Winter S; Rausch S; Fisel P; Hennenlotter J; Kruck S; Stenzl A; Wahrheit J; Sonntag D; Scharpf M; Fend F; Agaimy A; Hartmann A; Bedke J; Schwab M
Eur Urol Focus; 2019 Jul; 5(4):608-618. PubMed ID: 29452772
[TBL] [Abstract][Full Text] [Related]
37. GPX8 regulates clear cell renal cell carcinoma tumorigenesis through promoting lipogenesis by NNMT.
Nguyen TTM; Nguyen TH; Kim HS; Dao TTP; Moon Y; Seo M; Kang S; Mai VH; An YJ; Jung CR; Kim JM; Park S
J Exp Clin Cancer Res; 2023 Feb; 42(1):42. PubMed ID: 36750850
[TBL] [Abstract][Full Text] [Related]
38. A role for SETD2 loss in tumorigenesis through DNA methylation dysregulation.
Javaid H; Barberis A; Chervova O; Nassiri I; Voloshin V; Sato Y; Ogawa S; Fairfax B; Buffa F; Humphrey TC
BMC Cancer; 2023 Aug; 23(1):721. PubMed ID: 37528416
[TBL] [Abstract][Full Text] [Related]
39. Immunohistochemistry Successfully Uncovers Intratumoral Heterogeneity and Widespread Co-Losses of Chromatin Regulators in Clear Cell Renal Cell Carcinoma.
Jiang W; Dulaimi E; Devarajan K; Parsons T; Wang Q; Liao L; Cho EA; O'Neill R; Solomides C; Peiper SC; Testa JR; Uzzo R; Yang H
PLoS One; 2016; 11(10):e0164554. PubMed ID: 27764136
[TBL] [Abstract][Full Text] [Related]
40. Histone methyltransferase SETD2: An epigenetic driver in clear cell renal cell carcinoma.
Yu M; Qian K; Wang G; Xiao Y; Zhu Y; Ju L
Front Oncol; 2023; 13():1114461. PubMed ID: 37025591
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]